Scilex Gets Orphan Drug Designation for Its Version of Colchicine

Dow Jones

04-17

By Josh Beckerman

Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.

The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.

Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.

The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

April 16, 2025 14:39 ET (18:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2528279819"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528279819\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2528279819?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528279819","market":"sg","top_or_hot":-1,"title":"Scilex Gets Orphan Drug Designation for Its Version of Colchicine","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n</p>\n<p>\n  The company's Gloperba, licensed from Romeg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n</p>\n<p>\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n</p>\n<p>\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 14:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scilex Gets Orphan Drug Designation for Its Version of Colchicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScilex Gets Orphan Drug Designation for Its Version of Colchicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-17 02:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n</p>\n<p>\n  The company's Gloperba, licensed from Romeg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n</p>\n<p>\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n</p>\n<p>\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 14:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2528279819","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528279819","pubTimestamp":1744828740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SCLX":"Scilex Holding Company"},"translate_title":"Scilex的秋水仙碱获得孤儿药称号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCLX":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n\n\n  The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n\n\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n\n\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 14:39 ET (18:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}